Q96
Conditions
Interventions
Group 1: Patients with Ullrich–Turner syndrome will undergo a one-time assessment including the “Turner-CVD” questionnaire on medical history, hormonal status, and quality of life, transthoracic echoc
Sponsors
Herzzentrum - Universitätsklinikum Bonn
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: - Confirmed diagnosis of Turner syndrome - Written informed consent
Exclusion criteria
Exclusion criteria: - Age < 18 years - Pregnancy - Intellectual impairment preventing participation in the registry
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Quantitative and qualitative characterization of molecular markers and genetic features to identify biomarkers as well as immunological and molecular biological mechanisms involved in the pathophysiology of cardiovascular disease, measured in blood from a single sample obtained at study inclusion. | — |
Secondary
| Measure | Time frame |
|---|---|
| Echocardiographic parameters to assess the severity and phenotype of valvular heart disease (e.g., effective orifice area, transvalvular gradients, extent of fibrosis and calcification, left ventricular function) will be measured during the single transthoracic echocardiography performed at study inclusion. Clinical symptoms (e.g., exertional dyspnea, syncope, chest pain, reduced exercise capacity) will be assessed once using a questionnaire at study inclusion. | — |
Countries
Germany
Contacts
Public ContactSebastian Zimmer
Herzzentrum - Universitätsklinikum Bonn
Outcome results
None listed